Chronic Obstructive Pulmonary Disease: Lifestyle Impact

Shashi Mathur, Pratibha Singh

Abstract


Respiratory infections, a global health priority according to the World Health Organization, cause around 7.5 million deaths annually, constituting 14% of global mortality. Beyond severe health implications, these diseases exacerbate social disparities and impose a substantial economic burden. Chronic obstructive pulmonary disease  (COPD) combines chronic bronchitis  (airway inflammation) and emphysema (air sac destruction) caused by prolonged exposure to irritants, and poor lifestyle choices lead to airway blockage and breathing difficulties. Lifestyle choices significantly influence health trajectories, evidenced by a consistent increase in “positive comfort” over time. A Chinese study highlights the correlation between adopting a healthy lifestyle and increased life expectancy. European health initiatives address these challenges, emphasizing early detection through large‑scale health camps to identify new cases and assess severity. Exacerbation and infections are primary triggers, with bacteria and viruses requiring antibiotic interventions. Awareness campaigns targeting causes, symptoms, and prevention, including childhood infection initiatives with influenza and pneumococcal vaccinations, are crucial. Motivating smoking cessation and encouraging whole grain, fruit, and vegetable consumption mitigate lung oxidative damage. Promoting physical activity and addressing environmental pollution contribute to overall lung health. Timely nutritional evaluations for newly diagnosed cases manage obesity and malnutrition and prevent further lung function deterioration. There is growing attention toward the influence of poor lifestyle choices like sedentary lifestyle, environmental exposure, and unhealthy dietary patterns on the increased risk of COPD development besides smoking. This essay explores these factors, recognizing the intricate interplay between lifestyle and COPD prevention and management.

Keywords


Air pollution; chronic respiratory disease; fiber; lung capacity; smoking; vaccination

Full Text:

PDF

References


Available from: https://www.who.int/newsroom/factsheets/ detail/chronicobstructivepulmonarydisease(copd), [Last accessed on 2023 May 16].

Glass RI, Rosenthal JP. International approach to environmental and lung health. A perspective from the Fogarty International Center. Ann Am Thorac Soc 2018;15:(Suppl 2), S10913. doi: 10.1513/AnnalsATS.201708685MG.

Wang C, Xu J, Yang L. Prevalence and risk factors of chronic disruptive lung disease in China (the China Pulmonary Health [CPH] study): A national crosssectional study. Lancet 2018;391:170617.

Samoliński B, Fronczak A, Włodarczyk A, Bousquet J. Council of the European Union conclusions on chronic respiratory diseases in children. Lancet 2012;379:e456.

Huber M, Knottnerus JA, Green L, van der Horst H, Jadad AR, Kromhout D, et al. How should we define health? BMJ 2011;343:d4163. doi: 10.1136/bmj.d4163.

Stenholm S, Head J, Kivimäki M, Kawachi I, Aalto V, Zins M, et al. Smoking, physical inactivity and obesity as predictors of healthy and diseasefree life expectancy between ages 50 and 75: a multicohort study. International journal of epidemiology 2016;45:126070.

Hellings PW, Borrelli D, Pietikainen S, Agache I, Akdis C, Bachert C, et al. European summit on the prevention and selfmanagement of chronic respiratory diseases: Report of the European Union Parliament Summit (29 March 2017). Clin Transl Allergy 2017;7:49. doi: 10.1186/s1360101701863.

Maddocks S, Camp P, Tang C. Engaging ethnically diverse populations in selfmanagement interventions for chronic respiratory diseases: A narrative rewiew. Pulm Ther 2023;9:195206.

National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Pulmonary Obstructive Disease in Adults in Primary and Secondary Care (Partial Update). London: National Clinical Guideline Centre; 2010.

Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;7:CD001287. doi: 10.1002/14651858.CD001287.pub6.

Decramer M, Ruttenvan Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of Nacetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC costutility study, BRONCUS): A randomised placebocontrolled trial. Lancet 2005;365:155260.

Huntsberry A, Won K. Managing Chronic and acute COPD exacerbations. US Pharm 2018;43:HS136.

Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Doubleblind, randomized, multicenter, placebocontrolled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004;17:2734.

Miravitlles M, Ferrer M, Pont A, Zalacain R, AlvarezSala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study. Thorax 2004;59:38795.

Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2015;21:27883.

Available from: https://goldcopd.org/wpcontent/uploads/2017/11/ GOLD2018v6.0FINALrevised20Nov_WMS.pdf, [Last accessed on 2018 Apr 26].

Calverley PM, SanchezToril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:15461.

Available from: https://www.elsevier.es/enrevistaopen respiratoryarchives11articulorolevaccinesincopd patientsS2659663622000376.

Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy 2011;66:2531.

Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and Nacetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009;103:54251.

Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomised placebocontrolled study. Lancet 2008;371:20138.

Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, et al. Highdose Nacetylcysteine in stable COPD: The 1year, doubleblind, randomized, placebocontrolled HIACE study. Chest 2013;144:10618.

Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. Twice daily Nacetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, doubleblind placebocontrolled trial. Lancet Respir Med 2014;2:18794.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49:1700214. doi: 10.1183/13993003.002142017.

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity and safety of a 13valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with PPSV23valent pneumococcal polysaccharide vaccine. Vaccine 2013;31:358593.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Ruttenvan Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093103.

Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Oncedaily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallelgroup study. Lancet Respir Med 2013;1:52433.

Bai JW, Chen XX, Liu S, Yu L, Xu JF. Smoking cessation affects the natural history of COPD. Int J Chron Obstruct Pulmon Dis 2017;12:33238.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18. doi: 10.1186/146599211218.

York NL, Kane C, Beaton K, Keown B, Mcmahan S. Identifying barriers to hospitalized patients' participation in a free smoking cessation support program. Medsurg Nurs 2017;26:2532.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009;374:68594.

van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;8:CD010744. doi: 10.1002/14651858.CD010744.pub2.

Doo JH, Kim SM, Park YJ, Kim KH, Oh YH, Kim JS, et al. Smoking cessation after diagnosis of COPD is associated with lower allcause and causespecific mortality: A nationwide populationbased cohort study of South Korean men. BMC Pulmonary Med 2023;23:237. doi: 10.1186/s12890023025331.

Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2013;11:CD009764. doi: 10.1002/14651858.CD009764. pub3.

Suzuki T, Yanai M, Yamaya M, SatohNakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest 2001;120:7303.

Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Crit Care Med 2008;178:113947.

Sethi S, Jones PW, Schmitt Terron M, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Respir Res 2010;11:10. doi: 10.1186/146599211110.

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network metaanalysis. Cochrane Database Syst Rev 2013;5:CD009329.

Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 2015;385:85766.

Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;5:CD002309. doi: 10.1002/14651858.CD002309.pub5.

Mihai A, Mititelu M, Matei M, Lupu EC, Streba L, Vladu IM, et al. Assessment of behavioral risk factors in chronic obstructive airway diseases of the lung associated with metabolic syndrome. J Clin Med 2024;13:1037. doi: 10.3390/jcm13041037.

Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:68998.

Uzun S, Djamin RS, Kluytmans JAJW, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, doubleblind, placebocontrolled trial. Lancet Respir Med 2014;2:3618.

GozziSilva SC, Teixeira FME, Duarte AJDS, Sato MN, Oliveira LM. Immunomodulatory role of nutrients: How can pulmonary dysfunctions improve? Front Nutr 2021;8:674258. doi: 10.3389/fnut.2021.674258.

Schwartz J, Weiss ST. Dietary factors and their relation to respiratory symptoms. The second national health and nutrition examination survey. Am J Epidemiol 1990;132:6776.

Kim KS, Park S. Impact of lungrelated polygenic risk scores on chronic obstructive pulmonary disease risk and their interaction with w3 fatty acid intake in middleaged and elderly individuals. Nutrients 2023;15:3062. doi: 10.1007/s00774024014965.

Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533:22239.

Bodner C, Godden D, Brown K, Little J, Ross S, Seaton A. Antioxidant intake and adultonset wheeze: A casecontrol study. Aberdeen WHEASE Study Group. Eur Respir J 1999;13:2230.

Hansoon C, Lyden E, Rennard S, Mannino DM, Rutten EPA, Hopkins R, et al. The relationship between dietary fiber intake and lung function in the national health and nutrition examination surveys. Annals Am Thorac Soc 2016;13:64350.

Anand S, Mande SS. Diet, microbiota and gutlung connection. Front Microbiol 2018;92147. doi: 10.3389/fmicb.2018.02147.

MoralesBrown L. Medically reviewed by Kubala J: How does diet affect COPD? 2020. MedicalNewsToday, https:// medicalnewstoday.com articles copddiet. [Last accessed on 2024 Nov 23].

Arslan S, Bozkurt C, Arslan M, Bulut H. Effects of adherence to the Mediterranean diet on fatigue and activities of daily living in geriatric individuals with COPD. Clin Nutr ESPEN 2023;54:43642.

Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Executive summary: Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147:88393.

Hanson C, Lyden E, Rennard S, Mannino DM, A Rutten EP, Hopkins R, et al. The relationship between dietary fiber intake and lung function in the National Health and Nutrition Examination Surveys. Annals of the American Thoracic Society 2016;13:64350.

Varraso R, Fung TT, Barr RG, Hu FB, Willett W, Camargo CA Jr. Prospective study of dietary patterns and chronic obstructive pulmonary disease among US women. Am J Clin Nutr 2007;86:48895.

Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014;189:15038.

Svanström H, Pasternak B, Hviid A. Cardiovascular risks with azithromycin. N Engl J Med 2013;369:5801.

Apte K, Salvi S. Household air pollution and its effects on health. F1000Rerearch.2016;5.

Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368:16658.

Leskinen T, Stenholm S, Aalto V, Head J, Kivimäki M, Vahtera J. Physical activity level as a predictor of healthy and chronic diseasefree life expectancy between ages 50 and 75. Age Ageing 2018;47:4239.

Wilken D, Garrido MV, Manuwald U, Baur X. Lung function in asbestosexposed workers,a systematic review and metaanalysis. J Occup Med Toxicol 2011;6:21. doi: 10.1186/17456673621.

Cullinan P, Muñoz X, Suojalehto H, Agius R, Jindal S, Sigsgaard T, et al. Occupational lung diseases: From old and novel exposures to effective preventive strategies. Lancet Respir Med 2017;5:44555.

Tashiro H, Takahashi K. Clinical impacts of interventions for physical activity and sedentary behavior on patients with chronic obstructive pulmonary disease. J Clin Med 2023;12:1631.

SolerCataluña JJ, MartinezGracía MA, Roman Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:92531.

Owen N, Healy GN, Matthews CE, Dunstan DW. Too much sitting: The population health science of sedentary behavior. Exerc Sport Sci Rev 2010;38:10513.

Lee IM, Shiroma EJ, Lobelo F, Erguder T, Karabulut E, Yildirim HH, et al. Impact of physical inactivity on the world's major noncommunicable diseases. Lancet 2012;380:21929.

Althoff T, Sosič R, Hicks JL, King AC, Delp SL, Leskovec J, et al. Largescale physical activity data reveal worldwide activity inequality. Nature 2017;547:3369.

DonaireGonzalez D, GimenoSantos E, Balcells E, de Batlle J, Ramon MA, Rodriguez E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J 2015;46:12819.

Hancox RJ, Rasmussen F. Does physical fitness enhance lung function in children and young adults? Eur Respir J 2018;51:1701374. doi: 10.1183/13993003.013742017.

Lim MS, Lee CH, Sim S, Hong SK, Choi HG. Physical activity, sedentary habits, sleep and obesity are allied with asthma, allergic rhinitis and atopic dermatitis in Korean minors. Yonsei Med J 2017;58:10406.

GarciaAymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and death in chronic unhelpful lung disease: A populationbased cohort study. Thorax 2006;61:7728.

Nakken N, Janssen DJA, van den Bogaart EHA, Wouters EFM, Franssen FM, Vercoulen JH, et al. Informal caregivers of patients with COPD: Home sweet home? Eur Respir Rev 2015;24:498504.

GarciaAymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smokingrelated lung function decline and reduces risk of chronic obstructive pulmonary disease. A populationbased cohort study. Am J Respir Crit Care Med 2007;175:45863.

Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Lung Society report: Key concepts and advances in lung help. Am J Respir Crit Care Med 2013;188:e1364.

Paneroni M, Simonelli C, Vitacca M, Ambrosino N. Aerobic exercise training in very severe chronic obstructive pulmonary disease: A orderly review and metaanalysis. Am J Phys Med Rehabil 2017;96:5418.

Cindy Ng LW, Mackney J, Jenkins S, Hill K. Does exercise training change physical activity in people with COPD? A systematic review and metaanalysis. Chron Respir Dis 2012;9:1726.

Mesquita R, Meijer K, Pitta F, Azcuna H, Goërtz YMJ, Essers JMN, et al. Changes in physical activity and sedentary behaviour following pulmonary rehabilitation in patients with COPD. Respir Med 2017;126:1229.

Coultas DB, Jackson BE, Russo R, Peoples J, Sloan J, Singh KP, et al. A lifestyle physical activity intervention for patients with chronic unruly lung disease. A randomized controlled trial. Ann Am Thorac Soc 2016;13:61726.

Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM, American Thoracic Society/European Respiratory Society Task Force on Policy in Pulmonary Rehabilitation. Increasing implementation and delivery of pulmonary rehabilitation: Key messages from the new ATS/ERS policy statement. Eur Respir J 2016;47:133641.

Maltais F, Bourbeau J, Shapiro S, Lacasse Y, Perrault H, Baltzan M, et al. Effects of homebased pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2008;149:86978.

Ambrosino N, Fracchia C. The role of telemedicine in patients with respiratory diseases. Expert Rev Respir Med 2017;11:893900.

Watz H, Pitta F, Rochester CL, GarciaAymerich J, ZuWallack R, Troosters T, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014;44:152137.

Vaz Fragoso CA, Beavers DP, Anton SD. Effect of structured physical activity on respiratory outcomes in sedentary elderly adults with mobility limitations. J Am Geriatr Soc 2016;64:5019.